Statement of FTC Chairman Joe Simons Regarding Federal Court Ruling in FTC v. AbbVie

Federal Trade Commission Chairman Joe Simons issued the following statement regarding the decision by the U.S. District Court for the Eastern District of Pennsylvania in the case FTC v. AbbVie. The court ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone replacement drug Androgel, and ordered $448 million in monetary […]

FTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc.

The Federal Trade Commission has approved a sublicense submitted by Mallinckrodt ARD Inc. granting West Therapeutic Development, LLC certain rights to develop and market the specialty drug Synacthen Depot in the United States. Synacthen Depot contains a synthetic version of adrenocorticotropic hormone, or ACTH, and is approved in Europe and elsewhere to treat infantile spasms, […]

Mallinckrodt Will Pay $100 Million to Settle FTC, State Charges It Illegally Maintained its Monopoly of Specialty Drug Used to Treat Infants

Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, have agreed to pay $100 million to settle Federal Trade Commission charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its monopoly in the U.S. market for adrenocorticotropic hormone (ACTH) drugs. Acthar […]

FTC Sues Pharmaceutical Companies for Illegally Blocking Consumer Access to Lower-Cost Versions of the Blockbuster Drug AndroGel

Note: A conference call for media with FTC Chairwoman Edith Ramirez will occur as follows: Date: Sept. 8, 2014Time: 1:00 p.m. ET Call-in lines, which are for media only, will open 15 minutes prior to the start of the call. Chairwoman Ramirez and FTC staff will be available to take questions from the media about […]